Fullerton-based Beckman Coulter Inc. reported higher third-quarter profits Tuesday but narrowed its profit forecast for the rest of the year.
The maker of medical diagnostic products said it now expects profits of $203 million to $206 million.
Earlier, the company expected profits of $200 million to $209 million.
The company’s shares were off about 3% on Tuesday with a market value of $4.4 billion.
Beckman expects sales growth of 7% to 9% to $2.71 billion to $2.76 billion.
For the third quarter, Beckman reported higher profits but softer sales because of slower business selling to medical researchers and a supply disruption.
Third-quarter profits rose 27% to $60 million. Excluding one-time items, Beckman earned $49.5 million. Wall Street had expected $48.4 million.
Sales rose by 6% from a year earlier to $669 million, but below Wall Street’s expected $683 million.
Slower sales to sales to academic researchers were behind the sales shortfall. The company also saw a delay in shipments of machines to analyze cells because of a supply disruption.
